Compound: 
GBR 1342
Primary Indications: 
Multiple myeloma, Solid Tumors
Target: 
CD38xCD3 (bispecific mAb)
details: 

GBR 1342, a CD38xCD3 bsAb based on Glenmark’s proprietary BEAT platform targets CD38, a clinical target in multiple myeloma and other malignancies of hematopoietic origin, as well as a variety of solid tumors. Results from preclinical assays in comparison to daratumumab, an FDA-approved monoclonal antibody targeting CD38, suggest that GBR 1342 has a potent antitumor effect on patient derived multiple myeloma cell lines.

For GBR 1342, a Phase 1, first-in-human study to determine the MTD in a bi-weekly dosing regimen in patients with refractory multiple myeloma is ongoing. Cohorts 1-9 have been completed, and the study continues with the enrolment of patients into Cohort 10. Glenmark plans to amend the current protocol to include a weekly dosing regimen in the current study in H2 CY 2019.

Percentage Completed: 
30.00
biological entity: 
Oncology